EC approves Bavencio to treat Merkel cell carcinoma

The European Commission approved Bavencio avelumab (MSB0010718C, PF-06834635) from Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) to treat metastatic Merkel cell carcinoma. The companies expect to initially launch the human IgG1 mAb against PD-L1 in Germany and the U.K. as early as October...